Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELP Study Extension: Long-Term Safety and Efficacy of Lanadelumab (DX-2930) in Hereditary Angioedema
2015-005255-27Phase 3Completed
- Sponsor
- Dyax Corp.
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lanadelumab in hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2), sponsored by Dyax Corp. Primary endpoint: Long-term safety of repeated subcutaneous administrations of DX-2930. Started May 2016; status: completed.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)
Beyond the preview
Go deeper on 2015-005255-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005255-27.